Skip to main content
A Singapore Government Agency Website How to identify
Official website links end with .gov.sg
Secure websites use HTTPS
Look for a lock () or https:// as an added precaution. Share sensitive information only on official, secure websites.
Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 if you are unsure if something is a scam.

National Drug Formulary

CILOXAN STERILE OPHTHALMIC OINTMENT 3 MG/G [SIN11265P]

Active ingredients: CIPROFLOXACIN HCL EQV CIPROFLOXACIN

View product's general information
Last updated on 9 October 2026

Product Info

CILOXAN STERILE OPHTHALMIC OINTMENT 3 MG/G

[SIN11265P]

Product information

Active Ingredient and Strength

CIPROFLOXACIN HCL EQV CIPROFLOXACIN - 3 MG/G

Dosage Form

OINTMENT

Manufacturer and Country

NOVARTIS MANUFACTURING NV - BELGIUM

Registration Number

SIN11265P

Licence Holder

NOVARTIS (SINGAPORE) PTE LTD

Forensic Classification

PRESCRIPTION ONLY MEDICINES

Anatomical Therapeutic Chemical (ATC) code

S01AX13

Prescription-only Medicines with Exemptions for Supply without Prescription

NA

Indication

3 Indications

Ocular Use:

• Ciloxan Eye Ointment is a synthetic, sterile, multiple dose, antimicrobial for topical ophthalmic use. Ciprofloxacin is a fluoroquinolone antibacterial.
Ciloxan Eye Ointment is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of microorganisms listed below:

Gram-Positive:
Staphylococcus aureus
Staphylococcus epidermidis
Streptococcus pneumoniae
Streptococcus Viridans Group

Gram-Negative:
Haemophilus influenza

Dosing

4 Dosage regimen and administration

Dosage Regimen
Apply a 1/2” ointment ribbon into the conjunctival sac 3 times a day on the first 2 days, then apply a 1/2” ointment ribbon 2 times a day for the next 5 days.

Special populations

Renal and hepatic Impairment
No studies have been performed in patients with renal or hepatic impairment.

Pediatric patients
Safety and effectiveness of CILOXAN Eye Ointment in pediatric patients below the age of two years have not been established.

Geriatric patients (65 years of age or above)
No dosage regimen adjustments is required in patients 65 years of age or above.

Method of administration

Ciloxan Eye ointment

  • For ocular use only

  • After cap is removed, if tamper evident snap collar is loose, it should be removed before using the product.

  • To avoid contamination, the tip of the tube should not touch any surface and should also not come into contact with the eye as this may cause injury to the eye. Keep the tube tightly closed when not in use.

  • Either nasolacrimal occlusion or gently closing the eyelid(s) after administration is recommended. This may reduce the systemic absorption of medicinal products administered via the ocular route and result in a decrease in systemic adverse reactions.

  • Patients should be advised not to wear contact lenses during treatment with CILOXAN eye ointment. Patients should remove contact lenses prior to application and wait at least 15 minutes before reinsertion.

  • If more than one topical ophthalmic product is being used, the medicines must be administered at least 5 minutes apart. Eye ointments should be administered last.

Contraindications

5 Contraindications

Hypersensitivity to the active substance, to other quinolones or to any of the excipients.